Dr Kimiora Henare obtained a BSc in Biomedical Sciences from the University of Auckland, before completing an MHSc at the Auckland Cancer Society Research Centre (ACSRC) under the supervision of Professor Lai-Ming Ching. He worked as a Research Technician at the Liggins Institute for two years, before returning to the ACSRC for doctoral studies under the supervision of Professors Lai-Ming Ching and Cristin Print, focussing on targeting the tumour microenvironment for the treatment of melanoma. After graduating with a PhD in 2014, Dr Henare received a Health Research Council (HRC) Eru Pomare Postdoctoral Fellowship, which included two years in Professor Frank Jirik's lab at the University of Calgary in Calgary, Alberta, Canada, and two years at the ACSRC in Professor Ching's lab. In 2019 he joined the Responsiveness to Māori team, in the Office of the Tumuaki and Te Kupenga Hauora Māori, and the Department of Oncology working as a Research Fellow in Professor Print's team on various clinical cancer genomics projects - including NETwork!, Genomics into Medicine, and the Rakeiora Programme.
Nationally, Dr Henare serves as a co-convenor and faculty member for the Summer internship for Indigenous Peoples in Genomics (SING) Aotearoa, a board member for Hei Āhuru Mōwai - Māori Cancer Leadership Aotearoa, and is the founding organiser and co-chair (alongside Dr George Laking) of He Akoranga Whakahoungia within the New Zealand Society for Oncology.
Chris Jackson is Professor of Oncology at the University of Otago, Dunedin, and a medical oncologist at Dunedin Hospital and Mercy Cancer Care. He treats patients with gut cancers and melanoma, teaches medical students and specialists-in-training, and is heavily involved in both national and international cancer policy and research.
He was previously the medical director of the Cancer Society of NZ, and his advocacy led to the funding of new cancer drugs, to the development of a new national cancer plan, and to the birth of the national cancer agency Te Aho o Te Kahu. He currently chairs the agency’s clinical committee and serves on the advisory board. In addition, he is on the programme board of the International Cancer Benchmarking Project, and is a founding member of the Common Sense Oncology movement.
He is a leading researcher in clinical trials in cancer, working with academics and companies to test and develop new treatments, and works alongside university lab groups to develop new tests for early detection of cancer and cancer recurrence, as well as methods for monitoring the growth of cancer or its response to treatment. He works with international groups on comparing clinical cancer outcomes between countries to identify how we can share information and learn from different cancer care systems to bring the best back to New Zealand.